相关实验视频
Updated: Aug 15, 2026

09:36
Changes in Mammary Gland Morphology and Breast Cancer Risk in Rats
Published on: October 16, 2010
概括
在老鼠中,周产期暴露于巴比塔尔会改变肝脏酶活性,在成年男性中增加亚拉托克素B1,这表明与癌症风险的联系.
科学领域:
- 毒理学 毒理学 毒理学
- 发育生物学 发展生物学
- 致癌的发生是致癌的产生.
背景情况:
- 肝脏微小体混合功能氧化酶 (MFO) 酶对于代谢异生菌至关重要.
- 周产期接触某些化合物可能会导致长期的健康影响.
- 甲素B1是一种已知的肝癌原体,需要代谢激活.
研究的目的:
- 调查围产期芬巴比他暴露对MFO活动的长期影响.
- 为了确定围产期的巴比特暴露是否会影响成年后代的阿弗拉托克素B1 adduct形成.
- 评估围产期药物暴露与癌症风险之间的潜在联系.
主要方法:
- 孕妇大鼠在哺乳期早期接受了费诺巴比他.
- 在成年男性后代中测量了肝脏MFO活性.
- 在成年男性后代的肝脏中量化了阿弗拉托克素B1添加物.
主要成果:
- 费诺巴比塔尔的使用导致了成年男性后代肝脏MFO活动的长期变化.
- 围产期暴露于巴比塔尔的后代表现出增加的阿弗拉托克辛B1 adduct 形成.
- 这些变化可能是永久的.
结论:
- 围产期暴露于可诱导药物代谢酶系统的持久变化.
- 改变的MFO活性可能会增加对致癌物质的敏感性,如阿弗拉托克辛B1.
- 围产期暴露于药理活性化合物可能会影响长期的癌症风险.
相关概念视频
Teratogenicity
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Mutagenicity and Carcinogenicity
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Factors Affecting Drug Biotransformation: Physicochemical and Chemical Properties of Drugs
A drug's physicochemical properties fundamentally influence its metabolism. For instance, a drug's molecular size and shape critically determine its interaction with enzymes and transporters — larger drugs may face difficulty reaching enzyme active sites, altering their metabolic pathways. The pKa of a drug, which establishes its ionization state, can impact its solubility and absorption, thereby influencing metabolism.
The drug's acidity or basicity is essential in determining the metabolic...
The drug's acidity or basicity is essential in determining the metabolic...
Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Drug Toxicity: Dose-Dependent Reactions
Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...

